World MS Day: accessible multiple sclerosis research
Currently, more than 2.9 million people are estimated to be living with multiple sclerosis (MS) worldwide, and that number appears to be rising. World MS Day takes place on 30 May every year and provides us with an opportunity to raise awareness, share resources and help campaign for change.
Our sister site Neuro Central has compiled a list of plain language summaries relating to MS that have been published in Neurodegenerative Disease Management. These articles present research in a way that is accessible and understandable to non-specialist audiences, including those affected by MS, their caregivers, healthcare professionals and decision makers.
What clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis
This summary explains the findings of a recent study that combined the results of over 1000 people across three clinical studies to assess the safety of evobrutinib. Evobrutinib is an oral medication being researched as a potential treatment for MS, rheumatoid arthritis and systemic lupus erythematosus. The three Phase II clinical trials involved over 1000 people who were administered evobrutinib to determine the appropriate dosage, safety profile and efficacy for treating specific medical conditions.
The results indicated that evobrutinib was well tolerated by the participants. However, the beneficial treatment effect of evobrutinib for people with rheumatoid arthritis and systemic lupus erythematosus was not deemed significant enough to continue further investigation for these conditions. Early results in people with MS showed a potential benefit, and additional studies are currently underway.
